During the Big Game, Pfizer unveiled a powerful new campaign as part of its bold mission to lead the fight against cancer.

• This marked the start of a year-long initiative aimed at empowering people to take charge of their health and understand their cancer risk factors.

Check out the ad and hear from Karin Tollefson, chief oncology medical officer at Pfizer, as she shares how the company is advancing the science that will shape the future of cancer care, while supporting millions of Americans on their health journey today.

1. The goal: Pfizer has set an ambitious goal of delivering eight cancer breakthroughs by 2030. Can you share how these breakthroughs could transform cancer care?

Tollefson: At Pfizer, we're leading a new era in cancer care with a vision of helping people with cancer live longer, better lives.

Our goal of delivering eight breakthroughs by 2030 is part of this commitment, focusing on major cancer types like breast, prostate, bladder, lung and blood cancers.

We're advancing new cutting-edge therapies across scientific modalities — like antibody-drug conjugates, small molecules and bispecific antibodies — that have the potential to transform the way cancer is treated.

With these innovations, we aim to not only improve survival rates but also look at how we might enhance the quality of life for patients and their families.

2. Why it's important: What drives Pfizer's commitment to leading the fight against cancer, and how is that reflected in the work happening today?

Tollefson: Pfizer's commitment stems from the urgent need to tackle one of the biggest health challenges of our time — cancer.

We're focused on outpacing and outsmarting the disease.

• Approximately 40% of our R&D budget is dedicated to oncology, underscoring our commitment to developing breakthroughs.

But it's not just about creating new treatments — it's about ensuring they reach the people who need them most.

3. The impact: Pfizer's portfolio includes cutting-edge therapies like antibody-drug conjugates (ADCs). How do you see these types of therapies transforming cancer care?

Tollefson: Fighting cancer requires bold innovation and deep scientific expertise, and at Pfizer, we're using diverse strategies to attack the disease from different angles.

Pfizer has deep, industry-leading technological and development expertise with the development of antibody-drug conjugates (ADCs), which are emerging as one of the most powerful tools in cancer treatment.

• ADCs specifically target cancer cells and deliver their cancer-killing drugs directly to tumors, with the intent of reducing damage to healthy cells and limiting side effects for patients.

This revolutionary technology enables powerful treatments across a broad range of cancers and has the potential to be more effective and less toxic than traditional chemotherapy.

4. How it's done: With 2.5 million people treated globally in 2024 with Pfizer's cancer medicines, how is Pfizer ensuring that innovation reaches the patients who need it most?

Tollefson: We know that breakthroughs only matter if they reach the patients who need them.

We partner with healthcare decision-makers, work with advocacy groups like the American Cancer Society, and push for policy changes to help ensure our treatments are accessible and affordable.

PfizerForAll is a platform that helps people manage their health and connect directly to care.

We're working to make sure everyone, no matter where they live, can access the best cancer care.

5. Take note: How has Pfizer's sponsorship initiatives with the American Cancer Society enhanced the support available to patients?

Tollefson: Pfizer and the American Cancer Society have a strong partnership focused on supporting patients through their cancer journey.

We're proud to have been named the American Cancer Society Corporate Partner of the Year in 2025, recognizing our shared dedication to patient care.

• Early detection is crucial, and the American Cancer Society CancerRisk360™ assessment, available via www.PfizerForAll, helps people better understand their cancer risk factors with consideration for genetics and lifestyle.

This tool helps empower individuals to take proactive steps in cancer prevention and early detection.

6. Here's what else: Beyond medicine, how does PfizerForAll play a role in Pfizer's commitment to helping patients navigate their healthcare journey?

Tollefson: PfizerForAll aims to help simplify healthcare for patients by providing a central hub of information across several therapeutic areas. It offers help with:

• Locating vaccines.
• Finding healthcare options through trusted partners.
• Understanding your disease risk factors.
• And more.

Since its launch last summer, it has helped millions of Americans manage their health more easily.

7. An expert take: What drives you in your work as chief oncology medical officer at Pfizer?

Tollefson: What drives me every day is deeply personal. Having lost both my husband and mother to cancer, I've experienced firsthand the devastating impact this disease can have on families and loved ones.

• My mother's lung cancer diagnosis came too late, and I often think about how different her outcome could have been with earlier detection.

The work we do at Pfizer isn't just about developing innovative therapies — it's about giving people more time and a better quality of life.

It's this purpose that drives me to push for breakthroughs, knowing that what we do today can change the lives of millions tomorrow.

Learn more at PfizerForAll.com.